Raymond_2021_J.Pers.Med_11_

Reference

Title : Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review - Raymond_2021_J.Pers.Med_11_
Author(s) : Raymond J , Imbert L , Cousin T , Duflot T , Varin R , Wils J , Lamoureux F
Ref : J Pers Med , 11 : , 2021
Abstract :

Dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban are direct oral anticoagulants (DOACs). Their inter-individual variability in pharmacodynamics and pharmacokinetics (transport and metabolism) is high, and could result from genetic polymorphisms. As recommended by the French Network of Pharmacogenetics (RNPGx), the management of some treatments in cardiovascular diseases (as antiplatelet agents, oral vitamin K antagonists, and statins) can rely on genetic testing in order to improve healthcare by reducing therapeutic resistance or toxicity. This paper is a review of association studies between single nucleotide polymorphisms (SNPs) and systemic exposure variation of DOACs. Most of the results presented here have a lot to do with some SNPs of CES1 (rs2244613, rs8192935, and rs71647871) and ABCB1 (rs1128503, rs2032582, rs1045642, and rs4148738) genes, and dabigatran, rivaroxaban, and apixaban. Regarding edoxaban and betrixaban, as well as SNPs in the CYP3A4 and CYP3A5 genes, literature is scarce, and further studies are needed.

PubMedSearch : Raymond_2021_J.Pers.Med_11_
PubMedID: 33440670

Related information

Citations formats

Raymond J, Imbert L, Cousin T, Duflot T, Varin R, Wils J, Lamoureux F (2021)
Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review
J Pers Med 11 :

Raymond J, Imbert L, Cousin T, Duflot T, Varin R, Wils J, Lamoureux F (2021)
J Pers Med 11 :